Generate a tailored SOP for Dr. Andrew West. Improve your application with a focused, well-structured draft.
Andrew Bradley West is a tenured professor at Duke University, principally appointed in the Department of Pharmacology and Cancer Biology, with secondary appointments in the Departments of Neurology, Neurobiology, and Cell Biology. His research is primarily concentrated on LRRK2 and alpha-synuclein, aiming to uncover critical mechanisms, biomarkers of neurodegeneration, and potential therapeutic targets for disease modification strategies. He serves as the director of the Duke Center for Neurodegeneration and Neurotherapeutics and is a founding member of the NINDS Parkinson Disease Biomarker Program steering committee. His academic journey began with undergraduate research under Todd Golde, followed by a thesis focused on parkin-linked Parkinson’s disease under John Hardy and Matthew Farrer. Post-doctoral training took place at UCLA and Johns Hopkins, concentrating on LRRK2-linked Parkinson disease. West has published over 100 articles on neurodegeneration and neurodevelopmental disorders and leads a laboratory that is a hub for LRRK2 and alpha-synuclein research, sharing resources and protocols with various laboratories and pharmaceutical companies.
Department of Biomedical Engineering (MS program)